| Gene symbol | C5 | Synonyms | C5D, C5a, C5b, CPAMD4, ECLZB | Type of gene | protein-coding |
| Chromosome | 9 | Map location | 9q33.2 | dbXrefs | |
| Description | complement C5 | ||||
| GTO ID | GTC1828 |
| Trial ID | NCT03364153 |
| Disease | Stargardt Disease |
| Altered gene | C5 |
| Therapeutic/Target gene | Target gene |
| Therapy | Aptamer |
| Treatment | Avacincaptad pegol|Zimura;ARC1905 |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease |
| Year | 2018 |
| Country | France|Germany|Hungary|Israel|Italy|Spain|United Kingdom|United States |
| Company sponsor | IVERIC bio, Inc. |
| Other ID(s) | OPH2005 |
| Cohort1: avacincaptad pegol | |||||||
|
|||||||
| Cohort2: Sham | |||||||
|
|||||||